Camarda Financial Advisors LLC decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 16.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,334 shares of the biopharmaceutical company’s stock after selling 271 shares during the period. Camarda Financial Advisors LLC’s holdings in Gilead Sciences were worth $87,000 as of its most recent SEC filing.
Several other institutional investors have also bought and sold shares of the business. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp boosted its stake in shares of Gilead Sciences by 95.7% in the 4th quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 554,083 shares of the biopharmaceutical company’s stock worth $34,658,000 after buying an additional 271,000 shares during the last quarter. Chilton Capital Management LLC lifted its position in Gilead Sciences by 3.5% during the fourth quarter. Chilton Capital Management LLC now owns 16,468 shares of the biopharmaceutical company’s stock valued at $1,030,000 after purchasing an additional 555 shares in the last quarter. Nicholas Company Inc. lifted its position in Gilead Sciences by 2.7% during the fourth quarter. Nicholas Company Inc. now owns 506,760 shares of the biopharmaceutical company’s stock valued at $31,697,000 after purchasing an additional 13,500 shares in the last quarter. Sectoral Asset Management Inc lifted its position in Gilead Sciences by 59.6% during the fourth quarter. Sectoral Asset Management Inc now owns 424,890 shares of the biopharmaceutical company’s stock valued at $26,577,000 after purchasing an additional 158,750 shares in the last quarter. Finally, AIMZ Investment Advisors LLC lifted its position in Gilead Sciences by 39.9% during the fourth quarter. AIMZ Investment Advisors LLC now owns 53,738 shares of the biopharmaceutical company’s stock valued at $3,361,000 after purchasing an additional 15,333 shares in the last quarter. 79.94% of the stock is owned by institutional investors and hedge funds.
Shares of Gilead Sciences stock traded down $0.02 during trading hours on Wednesday, hitting $66.50. The company’s stock had a trading volume of 5,232,893 shares, compared to its average volume of 7,266,858. Gilead Sciences, Inc. has a 12-month low of $60.32 and a 12-month high of $79.61. The company has a quick ratio of 3.53, a current ratio of 3.62 and a debt-to-equity ratio of 1.09. The company has a market capitalization of $84.60 billion, a price-to-earnings ratio of 10.81, a PEG ratio of 0.81 and a beta of 1.14.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.53 by $0.23. Gilead Sciences had a return on equity of 37.98% and a net margin of 26.40%. The firm had revenue of $5.28 billion for the quarter, compared to analysts’ expectations of $5.29 billion. During the same period in the previous year, the firm posted $1.48 earnings per share. The business’s revenue was up 3.8% compared to the same quarter last year. On average, equities analysts expect that Gilead Sciences, Inc. will post 6.6 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Thursday, June 13th. This represents a $2.52 annualized dividend and a dividend yield of 3.79%. Gilead Sciences’s dividend payout ratio (DPR) is 40.98%.
In other news, Director Richard James Whitley sold 9,534 shares of Gilead Sciences stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $65.48, for a total value of $624,286.32. Following the sale, the director now directly owns 34,669 shares of the company’s stock, valued at $2,270,126.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John Francis Cogan sold 2,700 shares of Gilead Sciences stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $65.07, for a total value of $175,689.00. Following the completion of the sale, the director now directly owns 57,560 shares in the company, valued at $3,745,429.20. The disclosure for this sale can be found here. Insiders sold 28,602 shares of company stock worth $1,863,445 over the last ninety days. Insiders own 0.20% of the company’s stock.
Several equities analysts recently weighed in on the company. Citigroup upgraded Gilead Sciences from a “neutral” rating to a “buy” rating in a research report on Wednesday. Credit Suisse Group assumed coverage on Gilead Sciences in a research report on Monday. They set a “neutral” rating and a $70.00 target price on the stock. Mizuho set a $88.00 target price on Gilead Sciences and gave the company a “buy” rating in a research report on Friday, May 17th. Evercore ISI reiterated a “buy” rating on shares of Gilead Sciences in a research report on Friday, May 17th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating and set a $87.00 target price on shares of Gilead Sciences in a research report on Tuesday, May 7th. Nine research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $81.00.
WARNING: “Camarda Financial Advisors LLC Has $87,000 Holdings in Gilead Sciences, Inc. (GILD)” was published by Sundance Herald and is the sole property of of Sundance Herald. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://sundanceherald.com/2019/05/22/camarda-financial-advisors-llc-lowers-stake-in-gilead-sciences-inc-gild.html.
About Gilead Sciences
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Recommended Story: How analysts view the yield curve
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.